



SHUKRA

PHARMACEUTICALS LTD.

12th November, 2022

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street, Mumbai.

Scrip Code: 524632

Sub: - Outcome of Board Meeting

Ref: - Regulation 30 of SEBI (Listing obligation and Disclosure Requirements) Regulation, 2015.

Dear Sir/Madam,

With reference to above subject and in compliance with the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. 12th November, 2022 at 03:00 p.m. and concluded at 5:15 p.m.:-

1. Considered, adopted and approved Unaudited Financial Results for the quarter and half year ended on 30th September, 2022 along with the Limited Review Report thereon.


(The copies of the aforesaid Financial Results along with the Limited Review Reports thereon are enclosed herewith.)

2. Reconstitution of the following Committees of the Company:

I. AUDIT COMMITTEE:

S. No.	Name of Committee Member	Position	Category
1	Ms. Bhoomiben Patel	Chairperson	Non-Executive Independent Director
2	Mr. Ashvin Trivedi	Member	Non-Executive Director
3	Mr. Rai Kavoorguthu Konark	Member	Non-Executive Independent Director

CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

II. NOMINATION AND REMUNERATION COMMITTEE:

S. No.	Name of Committee Member	Position	Category
1	Ms. Bhoomiben Patel	Chairperson	Non-Executive Independent Director -
2	Mr. Ashvin Trivedi	Member	Non-Executive Director
3	Mr. Rai Kavoorguthu Konark	Member	Non-Executive Independent Director -

III. STAKEHOLDER RELATIONSHIP COMMITTEE:

S. No.	Name of Committee Member	Position	Category
1	Ms. Bhoomiben Patel	Chairperson	Non-Executive Independent Director -
2	Mr. Ashvin Trivedi	Member	Non-Executive Director
3	Mr. Rai Kavoorguthu Konark	Member	Non-Executive Independent Director -

3. Reviewed business of the company.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully

For Shukra Pharmaceuticals Limited


Bhoomiben Patel
Director
(DIN: 08316893)

CIN : L24231GJ1993PLC019079

SHUKRA PHARMACEUTICALS LIMITED

CIN: L24231GJ1993PLC019079

3rd Floor, Dev House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380 052


STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HAIF YEAR ENDED 30TH September, 2022

Rs. In Lakhs (Except EPS)

Sr. No.	Particulars	QUARTER ENDED			Half Yearly		Year Ended
		30.09.2022 (Unaudited)	30.06.2022 (Unaudited)	30.09.2021 (Unaudited)	30-09-2022 (Unaudited)	30-09-2021 (Unaudited)	31.03.2022 (Audited)
1	Income from Operations						
I	Revenue from Operations	372.06	656.57	298.31	1,028.63	594.52	2,048.60
	(a) Net Sales/ Income from Operations	372.06	656.57	298.31	1,028.63	594.52	2,048.60
II	Other Income	2.85	0.81	240.24	3.66	262.82	8.10
	Total Income from Operations (I+II)	374.91	657.38	538.55	1,032.29	857.34	2,056.70
2	Expenses						
	(a) Cost of materials consumed	237.51	368.05	344.44	605.55	420.55	1,107.99
	(b) Purchase of Stock-in Trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, and work-in-progress and stock in trade	(87.84)	32.95	(78.72)	(54.89)	(78.72)	(73.41)
	(d) Employee Benefit Expenses	116.67	133.73	113.16	250.40	217.11	490.45
	(e) Finance Cost	4.32	11.54	2.08	15.87	3.91	28.66
	(f) Depreciation & Amortisation Expenses	45.13	42.15	36.84	87.28	73.68	166.21
	(g) Other Expenses	58.45	26.45	113.53	84.89	208.64	235.00
	Total Expenses	374.24	614.87	531.33	989.11	845.16	1,954.90
3	Profit / (Loss) before Exceptional and Extra ordinary items and Tax (1-4)	0.67	42.51	7.23	43.18	12.18	101.80
4	Exceptional Items	-	-	-	-	-	-
5	Profit / (Loss) before Extra ordinary items and Tax (3-4)	0.67	42.51	7.23	43.18	12.18	101.80
6	Extra ordinary items	-	-	-	-	-	-
7	Net Profit / (Loss) from Ordinary Activities before Tax(5-6)	0.67	42.51	7.23	43.18	12.18	101.80
8	Tax Expenses						
	I. Current Tax	(9.04)	9.04	0.66	-	1.90	17.58
	II. Deferred Tax	1.28	0.68	4.64	1.95	4.64	5.62
	II. Tax of Earlier Year	0.80	-	-	0.80	-	3.53
	IV. MAT Credit Entitlement	-	-	-	-	-	-
9	Net Profit / (Loss) for the Period (7-8)	7.64	32.79	1.93	40.43	5.63	75.07
10	Other Comprehensive Income						
	Remeasurement of defined benefit plans	-	-	-	-	-	-
	Prior Period Adjustments & Expenses	-	-	-	-	-	-
11	Total Comprehensive Income for the period (9+10)	7.64	32.79	1.93	40.43	5.63	75.07
12	Paid up Equity Share Capital (F. V. of Re. 1/- Each)	156.57	156.57	156.57	156.57	156.57	156.57
13	Other Equity excluding Revaluation Reserve	10.00	10.00	10.00	10.00	10.00	10.00
14	Earnings per Share (of Re. 1/- each) :						
	(a) Basic-Rs	0.49	2.09	0.12	2.58	0.36	4.79
	(b) Diluted-Rs	0.49	2.09	0.12	2.58	0.36	4.79

NOTES:

- The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 12th November, 2022. The statutory auditors have carried out review of the results for the quarter ended September 30, 2022 and have expressed an unqualified audit opinion.
- The figures for the previous period/year have been regrouped /reclassified, wherever necessary.
- This Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- The Disclosure is as per Regulation 33 of SEBI (Listing Obligations & Discloser Requirements) Regulations, 2015.
- The Company is operating in single segment, so above results are for single segment only.

For and on behalf of Board of Directors of
SHUKRA PHARMACEUTICALS LIMITED

 BHOOMIBEN PATEL
 Director
 DIN:08316893
Date: 12-11-2022
Place: Ahmedabad

SHUKRA PHARMACEUTICALS LIMITED
CIN: L24231GJ1993PLC019079
Unaudited Balance Sheet as at 30th September, 2022

Particulars	As at September 30, 2022	As at March 31, 2022
Assets		
Non-current assets		
Property, plant and equipment	1,838.11	1,757.95
Capital work-in-progress	156.77	166.17
Financial Assets		
Investments	20.73	20.42
Trade receivables	-	-
Loans	-	-
Other financial assets	-	-
Other non-current assets	-	-
Deferred tax assets (net)	-	-
	2,015.61	1,944.55
Current assets		
Inventories	279.46	395.40
Financial assets		
(i) Investments	-	-
(ii) Trade receivables	306.11	740.08
(iii) Cash and cash equivalents	111.54	8.54
(iv) Bank balance other than cash and cash equivalents	-	-
(v) Loans	300.25	311.81
(vi) Other financial assets	-	-
Income tax assets (net)	-	-
Other current assets	129.62	110.91
	1,126.98	1,566.74
	3,142.59	3,511.28
Total assets		
Equity and liabilities		
Equity		
Equity share capital	156.57	156.57
Other equity	1,518.86	1,478.43
Total equity	1,675.43	1,635.00
Liabilities		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	139.52	312.68
Provisions	-	-
Deferred tax liabilities (net)	327.92	325.96
Other non-current liabilities	-	-
	467.44	638.65
Current liabilities		
Financial liabilities		
(i) Borrowings	33.60	24.97
(ii) Trade payables	839.52	858.99
(iii) Other financial liabilities	-	-
Provisions	-	-
Other current liabilities	126.60	353.68
Liabilities for current tax (net)	-	-
Other Provisions	-	-
	999.72	1,237.63
Total liabilities	1,467.16	1,876.28
Total equity and liabilities	3,142.59	3,511.28

For and on behalf of Board of Directors of


BHOOMIBEN PATEL
 Director
 DIN:08316893

Date: 12-11-2022
 Place: Ahmedabad


SHUKRA PHARMACEUTICALS LIMITED
CIN: L24231GJ1993PLC019079
Statement of Cash Flows for the Half year ended September 30, 2022

Particulars	For the Half year ended September 30, 2022	For the Half year ended September 30, 2021
Cash flow from operating activities		
Profit before tax as per statement of profit and loss	43.18	5.63
Adjustments for:		
Depreciation and amortisation	87.28	73.68
Interest income		
Interest expense	15.87	4.09
Operating profit before working capital changes	146.33	83.40
Movements in working capital :		
(Increase)/decrease in trade receivables	433.98	1.07
(Increase)/decrease in inventories	115.93	(139.32)
(Increase)/decrease in financial assets		
(Increase)/decrease in other assets	(7.15)	(8.58)
Increase/(decrease) in trade payables	(19.47)	5.76
Increase/(decrease) in other liabilities	(207.02)	39.04
Cash generated from operations	462.60	(18.63)
Direct taxes (paid)/refund (net)	(12.20)	6.55
Net cash Inflow / (Outflow) from operating activities (A)	450.40	(12.08)
Cash flows from investing activities		
Purchase of property, plant and equipments (Including capital work in progress, capital advances and capital creditors)	(158.04)	(91.93)
Proceeds from sale of fixed assets		
Interest received		
Interest expense		
(Purchase)/sale of investment	(0.31)	
Net cash inflow from investing activities (B)	(158.35)	(91.93)
Cash flows from financing activities		
Proceeds from long-term borrowing	(173.18)	69.88
Proceeds from bank/FI borrowing		
Interest paid	(15.87)	(4.09)
Net cash Inflow from financing activities (C)	(189.05)	65.79
Net increase / (decrease) in cash & cash equivalents (A + B + C)	103.00	(38.22)
Cash and cash equivalents at the beginning of the year	8.54	41.02
Cash and cash equivalents at the end of the period	111.54	2.80
Notes:		
Component of cash and cash equivalents		
Cash on hand	3.22	0.35
Balances with scheduled bank		
On current accounts	108.33	2.44
Cash and Cash Equivalents at the End of the period	111.54	2.80

Note :

(1) The Statement of Cash flows has been prepared under the Indirect method as set out in Ind AS 7 – Statement of Cash flows notified under section 133 of The Companies Act, 2013, read together with paragraph 7 of the Companies (Indian Accounting Standard) Rules 2015 (as amended).

Date: 12-11-2022
Place: Ahmedabad

For and on behalf of Board of Directors of
SHUKRA PHARMACEUTICALS LIMITED

BHOOMIBEN PATEL
Director
DIN:08316893

Independent Auditor's Limited Review Report on Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors of
SHUKRA PHARMACEUTICALS LIMITED

We have reviewed the accompanying statement of unaudited standalone financial results of **SHUKRA PHARMACEUTICALS LIMITED** (the "Company") for the quarter ended September 30, 2022 and year to date from April 01, 2022 to September 30, 2022 (the "Statement") being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended (the 'Listing Regulations').

This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS') prescribed under section 133 of The Companies Act, 2013, read with relevant Rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter – No such thing requires to be mentioned hence our conclusion is not modified in respect of this matter.

Place: Ahmedabad
Date: November 12, 2022

For MAAK and Associates
Chartered Accountants
FRN: 135024W



Marmik Shah
Partner
M. No. 133926
UDIN:22133926BCXKCI759

